Papers - OKAMOTO Teppei
-
Serum Serotonin Levels as a Potential Risk Factor for Overactive Bladder in a Community-Dwelling Population: A Four-Year Longitudinal Study.
Fukushima T, Okamoto T, Hamaya T, Kodama H, Fujita N, Yamamoto H, Imai A, Nakaji S, Hatakeyama S.
Lower Urinary Tract Symptoms 2026.7
-
Overactive Bladder Symptoms as a Predictor of Longitudinal Decline in Grip Strength in Community-Dwelling Men: A 4-Year Longitudinal Study.
Sato H, Okamoto T, Hamaya T, Kodama H, Narita T, Mikami J, Fujita N, Yamamoto H, Imai A, Murashita K, Nakaji S, Hatakeyama S.
Lower Urinary Tract Symptoms 2026.3
-
The long-term impact of mild COVID-19 on cardiovascular disease and mortality in patients on hemodialysis: a post-Omicron era retrospective observational study.
Okamoto A, Okamoto T, Ichiyama T, Fukushima T, Omizo S, Asanuma H, Sato H, Sakurai H, Yoneyama A, Yoneyama F, Ishii N, Oishi T, Tanaka R, Miura H, Hamaya T, Kodama H, Fujita N, Murasawa H, Yamamoto H, Imai A, Saitoh H, Hatakeyama S, Ohyama C, Suzuki T.
Renal Failure 2025.6
-
Pre-transplant tacrolimus fluctuations predict BK virus infection risk in kidney transplants
Hisashi Sakurai, Teppei Okamoto, Anna Yoneyama, Fumiya Yoneyama, Tomoko Hamaya, Hirotake Kodama, Naoki Fujita, Hayato Yamamoto, Kazuyuki Mori, Takeshi Fujita, Atushi Imai, Reiichi Murakami, Hirofumi Tomita,Shingo Hatakeyama, Chikara Ohyama
Clinical and Experimental Nephrology 2025.3
-
パイロット研究；抗癌剤治療を要する進行尿路上皮癌患者を対象とした人参養栄湯によるサルコペニア予防効果の検討（単施設、単群、非盲検化試験）
岡本 哲平
新薬と臨床 73 ( 8 ) 759 - 769 2024.8
-
Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8
Kento Morozumi,Koji Mitsuzuka,Shintaro Narita,Masahiro Takahashi,Sadafumi Kawamura,Tatsuo Tochigi,Yoichi Arai,Senji Hoshi,Jiro Shimoda,Shigeto Ishidoya,Teppei Okamoto,Shingo Hatakeyama,Toshihiko Sakurai,Norihiko Tsuchiya,Chikara Ohyama,Tomonori Habuchi,Akihiro Ito
2022.1
-
The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan
Okuyama Y, Okamoto T, Sasaki D, Ozaki K, Songee J, Hatakeyama S, Mikami T, Ohyama C.
International Urology and Nephrology 2021.10
-
Butyrylcholinesterase level as an independent prognostic factor for overall survival in patients on maintenance hemodialysis: a single-center retrospective study
Fukushi K, Okamoto T, Ozaki Y, Ozaki K, Sasaki D, Miura Y, Okuyama Y, Tanaka Y, Imanishi K, Hatakeyama S, Saitoh F, Ohyama C.
Clinical and Experimental Nephrology 2021.9
-
Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Shinohara M, Yamamoto H, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Kodama H, Fujita N, Okamoto T, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S.
International Journal of Urology 2026.3
-
Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real-World Multicenter Retrospective Study.
Tanaka R, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Kodama H, Fujita N, Okamoto T, Yamamoto H, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S.
International Journal of Urology 2026.1
-
Immediate Postoperative cfDNA Elevation Predicts Pain After Robot-Assisted Radical Prostatectomy.
Ishii N, Yoneyama T, Minakawa S, Konishi S, Kodama H, Narita T, Mikami J, Fujita N, Okamoto T, Yamamoto H, Imai A, Ohyama C, Hatakeyama S.
International Journal of Urology 2026.1
-
Integrated Assessment of Percentage α2,3-Linked Sialylated Prostate-specific Antigen and the Prostate Health Index with Magnetic Resonance Imaging for Detection of Clinically Significant Prostate Cancer.
Oishi T, Yoneyama T, Miura Y, Hamaya T, Kodama H, Narita T, Mikami J, Fujita N, Okamoto T, Yamamoto H, Imai A, Ohyama C, Hatakeyama S.
European Urology Open Science 2025.12
-
Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study
Ishii N, Sekine Y, Shinohara M, Kawashima Y, Mori K, Kobayashi M, Numakura K, Mikami J, Fujita N, Okamoto T, Yoneyama T, Tabata R, Sato S, Habuchi T, Ohyama C, Hatakeyama S.
Cancer Medicine 2025.9
-
PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Sasaki D, Yoneyama T, Yoneyama F, Ozaki K, Ozaki Y, Miura Y, Fujita N, Okamoto T, Yamamoto H, Goto S, Yoshizawa T, Kurose A, Kijima H, Ohyama C, Hatakeyama S.
International Journal of Urology 2025.9
-
The Effects of the Blood-Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies.
Miura H, Hamaya T, Yoneyama T, Shimoyama T, Tsushima F, Togashi K, Miura Y, Yoneyama A, Sato H, Omizo S, Mori K, Kodama H, Fujita N, Okamoto T, Yamamoto H, Kakeda S, Ohyama C, Hatakeyama S.
Prostate 2025.8
-
Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
Yoneyama F, Shinohara M, Kawashima Y, Yoneyama A, Ishii N, Oishi T, Tanaka R, Miura H, Kodama H, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Sato S, Ohyama C, Hatakeyama S.
International Journal of Urology 2025.8
-
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.
Fukushima T, Numakura K, Shinohara M, Kawashima Y, Sekine Y, Mori K, Kobayashi M, Asanuma H, Ichiyama T, Sakurai H, Ozaki K, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Sato S, Habuchi T, Ohyama C, Hatakeyama S.
Scientific Reports 2025.7
-
Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population. Prostate.
Miura Y, Yoneyama T, Yamamoto H, Suzuki H, Otsubo T, Fujita E, Tsushima F, Goto S, Okamoto T, Fujita N, Ishiyama M, Yoshizawa T, Kakeda S, Hatakeyama S, Ohyama C.
Prostate 2025.3
-
Multicenter, international, retrospective study of prognostic factors for Ra223.
Oishi T, Luo HL, Hatayama Y, Kawaguchi H, Sasaki D, Tanaka R, Ishii N, Mikami J, Okamoto T, Yamamoto H, Aoki M, Su YL, Chen YH, Chang YH, Chen YT, Wang HJ, Ohyama C, Hatakeyama S.
Scientific Reports 2025.3
-
Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study
Kai Ozaki, Hayato Yamamoto, Yuya Sekine, Hirotaka Horiguchi, Shogo Hosogoe, Jotaro Mikami, Naoki Fujita, Noriko Tokui, Kazutaka Okita, Teppei Okamoto, Kanami Mori, Mizuki Kobayashi, Kazuyuki Numakura, Takahiro Yoneyama, Ryuji Tabata, Satoshi Sato, Tomonori Habuchi, Chikara Ohyama, Shingo Hatakeyama
International Journal of Clinical Oncology 2025.3